Aquestive Therapeutics, Inc.
AQST
$6.51
-$0.18-2.69%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -50.23% | -27.65% | -10.14% | 4.15% | 51.79% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -50.23% | -27.65% | -10.14% | 4.15% | 51.79% |
| Cost of Revenue | 0.77% | -16.79% | -3.40% | -7.52% | -31.60% |
| Gross Profit | -65.05% | -33.87% | -13.84% | 10.98% | 135.10% |
| SG&A Expenses | 11.88% | 78.43% | 67.63% | 64.20% | 54.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.62% | 33.67% | 48.66% | 41.96% | 14.87% |
| Operating Income | -20,769.09% | -116.20% | -247.20% | -248.76% | 101.31% |
| Income Before Tax | -393.55% | -78.75% | -113.10% | -429.15% | 50.16% |
| Income Tax Expenses | -- | -- | -113.86% | -- | -- |
| Earnings from Continuing Operations | -393.55% | -78.75% | -110.27% | -465.55% | 52.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -393.55% | -78.75% | -110.27% | -465.55% | 52.61% |
| EBIT | -20,769.09% | -116.20% | -247.20% | -248.76% | 101.31% |
| EBITDA | -4,418.46% | -119.73% | -292.42% | -284.81% | 106.63% |
| EPS Basic | -351.66% | -37.75% | -54.93% | -301.27% | 70.10% |
| Normalized Basic EPS | -191.78% | -37.83% | -67.64% | -276.19% | 51.33% |
| EPS Diluted | -351.66% | -37.75% | -54.93% | -312.70% | 70.10% |
| Normalized Diluted EPS | -191.78% | -37.83% | -67.64% | -276.19% | 51.33% |
| Average Basic Shares Outstanding | 9.26% | 29.73% | 35.71% | 40.82% | 58.52% |
| Average Diluted Shares Outstanding | 9.26% | 29.73% | 35.71% | 40.82% | 58.52% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |